BREYANZI Seeks Longer Patent Life: FDA Innovation Balance
Published Date: 6/20/2025
Notice
Summary
The FDA has officially set the review period for BREYANZI, a special medicine made from human cells. This means the company can ask for extra time on their patent to protect their invention. If approved, this could give them more exclusive rights before others can copy it, affecting when generic versions might appear and potentially impacting market competition and profits.
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in